bjh

british journal of haematology

Volume 125, 2004 Pages 1–828

Issue 1, April-I 2004

Images in Haematology

1 **Vascular endothelial growth factor and interleukin 6 expression by Hodgkin/Reed-Sternberg cells**
T. Yokote, T. Akioka, S. Oka, S. Nakayama, T. Yamano, S. Hara, M. Tsuji and T. Hanafusa

2 **Chédiak–Higashi syndrome**
L. M. Barton, P. Roberts, V. Trantou, C. Haworth, H. Kelsey and T. Blamires

Reviews

3 **New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies**
F. Locatelli and P. De Stefano

12 **Plasminogen activator inhibitor 1 (PAI-1): *in vitro* activities and clinical relevance**
A. J. G. Horrevoets

Annotation

24 **Treatment advances in multiple myeloma**
G. Tricot, B. Barlogie and F. Van Rhee

Haematological Malignancy

31 **Overexpression of the Ikaros 6 isoform is restricted to t(4;11) acute lymphoblastic leukaemia in children and infants and has a role in B-cell survival**
A. Ruiz, J. Jiang, H. Kempski and H. J. M. Brady

38 **Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma**
T. Hashimoto, M. Abe, T. Oshima, H. Shibata, S. Ozaki, D. Inoue and T. Matsumoto

42 **Elevated levels of transferrin receptor 2 mRNA, not transferrin receptor 1 mRNA, are associated with increased survival in acute myeloid leukaemia**
T. Nakamaki, H. Kawabata, B. Saito, M. Matsunawa, J. Suzuki, D. Adachi, S. Tomoyasu and H. P. Koeffler

Transplantation

50 **Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions**
M. Krampera, F. Venturini, F. Benedetti, A. Oliani, S. Carolei, C. Visco, H. Aqel, G. Pizzolo and G. Scroccaro

58 **Transplantation of highly purified CD34$^+$ progenitor cells from alternative donors in children with refractory severe aplastic anaemia**
M. Benesch, C. Urban, K. W. Sykora, W. Schwinger, F. Zintl, H. Lackner, P. Lang and R. Handgretinger

64 **The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant**
H. Chang, S. Sloan, D. Li, L. Zhuang, Q.-L. Yi, C. I. Chen, D. Reece, K. Chun and A. K. Stewart

Platelets, Haemostasis and Thrombosis

69 **Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients**
P. Chowdhury, A. G. Saayman, U. Paulus, G. P. Findlay and P. W. Collins

74 **Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation**
K. N. Ekdahl, A. A. Bengtsson, J. Andersson, G. Elgue, L. Rönnblom, G. Sturfelt and B. Nilsson

Short report 79 ***In vivo* and *in vitro* effects of different anaesthetics on platelet function**
P. L. Dordoni, L. Frassanito, M. F. Bruno, R. Proietti, R. De Cristofaro, G. Ciabattoni, G. Ardito, R. Crocchiolo, R. Landolfi and B. Rocca

Transfusion

83 **Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products**
P. Rebulla, F. Morelati, N. Revelli, M. A. Villa, C. Paccapelo, A. Nocco, N. Greppi, M. Marconi, A. Cortelezzi, N. Fracchiolla, G. Martinelli and G. L. Deliliers

Correspondence

90 **Incidence of idiopathic thrombocytopenic purpura among adults**
H. Frederiksen and K. Schmidt

90 **Response to Frederiksen and Schmidt**
A. J. Neylon, P. W. G. Saunders, M. R. Howard, S. J. Proctor and P. R. A. Taylor

91 **Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid**
V. Perifanis, T. Vyzantiadis, S. Vakalopoulou, K. Tziomalos, V. Garypidou, M. Athanassiou-Metaxa and F. Harsoulis

93 **Bisphosphonate treatment for the management of osteoporosis in beta-thalassaemia**
E. Voskaridou and E. Terpos

94 **Adult T-biphenotypic acute leukaemia: clinical and biological features and outcomes**
B. J. Bain

95 **Use of recombinant factor VIIa in inherited platelet disorders**
M. Kaleelrahman, A. Minford and L. A. Parapia

96 **Thalidomide in patients with multiple myeloma and renal failure**
F. Fakhouri, H. Guerraoui, C. Presne, J. Peltier, R. Delarue, P. Muret and B. Knebelmann

98 **Is once-weekly epoetin beta 'highly effective' in treating anaemia in patients with lymphoproliferative malignancy?**
C. Bokemeyer, T. Littlewood and M. Aapro

99 **Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production**
M. Cazzola

100 **Epoetin once weekly in anaemic patients with cancer**
B. Coiffier

101 **Response to Dr Coiffier**
M. Hedenus for the 20000161 Darbepoetin Alfa Study Group

Announcement

103 **Associazione Donatori Midollo Osseo International Award 2004**

Issue 2, April-II 2004

Images in Haematology

105 **Erythropoietin-producing cerebellar tumour**
I. Miyoshi, T. Saito, H. Taguchi and Y. Ohtsuki

106 **Copper deficiency anaemia**
I. Miyoshi, T. Saito and Y. Iwahara

Reviews

107 **Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction**
P. Ljungman

117 **The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined?**
J. P. V. Pinheiro and J. Boos

Haematological Malignancy

128 **The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia**
A. S. Kamiguti, E. S. Lee, K. J. Till, R. J. Harris, M. A. Glenn, K. Lin, H. J. Chen, M. Zuzel and J. C. Cawley

141 **Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target**
T. Decker, S. Hipp, I. Hahntow, F. Schneller and C. Peschel

149 **Early response predicts thalidomide efficiency in patients with advanced multiple myeloma**
A. Waage, P. Gimsing, G. Juliusson, I. Turesson, N. Gulbrandsen, T. Eriksson, M. Hjorth, J. L. Nielsen, S. Lenhoff, J. Westin and F. Wislöff for the Nordic Myeloma Study Group

156 **Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma**
S. B. Khan, T. Maududi, K. Barton, J. Ayers and S. Alkan

162 **Early response to therapy and survival in multiple myeloma**
C. G. Schaar, J. C. Kluin-Nelemans, S. le Cessie, P. F. H. Franck, M. C. te Marvelde and P. W. Wijermans

167 **A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells**
J. Bruenke, B. Fischer, K. Barbin, K. Schreiter, Y. Wachter, K. Mahr, F. Titgemeyer, M. Niederweis, M. Peipp, S. J. Zunino, R. Repp, T. Valerius and G. H. Fey

180 **CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival**
S. Ogawa, M. Yamaguchi, K. Oka, M. Taniguchi, M. Ito, K. Nishii, K. Nakase, T. Ohno, K. Kita, T. Kobayashi and H. Shiku

187 **Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome**
M. M. T. El-Zimaity, H. Kantarjian, M. Talpaz, S. O'Brien, F. Giles, G. Garcia-Manero, S. Verstovsek, D. Thomas, A. Ferrajoli, K. Hayes, B. Nebiyou Bekele, X. Zhou, M. B. Rios, A. B. Glassman and J. E. Cortes

196 **Prospective clinical evaluation of a LightCycler™-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients**
D. Buchheidt, M. Hummel, D. Schleiermacher, B. Spiess, R. Schwerdtfeger, O. A. Cornely, S. Wilhelm, S. Reuter, W. Kern, T. Südhoff, H. Mörz and R. Hehlmann

203 **CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias**
F. Buccisano, F. M. Rossi, A. Venditti, G. Del Poeta, M. C. Cox, E. Abbruzzese, M. Rupolo, M. Berretta, M. Degan, S. Russo, A. Tamburini, L. Maurillo, M. I. Del Principe, M. Postorino, S. Amadori and V. Gattei

Short report 213 **T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia**
J. Westermann, C. Schlimper, G. Richter, J. Mohm, B. Dörken and A. Pezzutto

Transplantation

217 **Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation**
D. H. Kim, J. G. Kim, S. K. Sohn, W. J. Sung, J. S. Suh, K. S. Lee and K. B. Lee

225 **Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution**
S. L. Petersen, H. O. Madsen, L. P. Ryder, A. Svejgaard, B. K. Jakobsen, H. Sengeløv, C. Heilmann, E. Dickmeiss and L. L. Vindeløv

Platelets, Haemostasis and Thrombosis

232 **The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura**
N. Cooper, R. Stasi, S. Cunningham-Rundles, M. A. Feuerstein, J. P. Leonard, S. Amadori and J. B. Bussel

Short report 240 **No deterioration after 13 years in a stability study of a rabbit brain, plain, thromboplastin, RBT 1010, in rubber-stoppered ampoules**
K. J. Stevenson, S. Craig, L. Goodman and F. B. Kanyike

Red Cells and Iron

243 **Diamond Blackfan anaemia in the UK: clinical and genetic heterogeneity**
K. A. Orfali, Y. Ohene-Abuakwa and S. E. Ball

253 ***Ex vivo*** **analysis of aberrant splicing induced by two donor site mutations in *PKLR* of a patient with severe pyruvate kinase deficiency**
R. van Wijk, A. C. W. van Wesel, A. A. M. Thomas, G. Rijksen and W. W. van Solinge

Issue 3, May-I 2004

Images in Haematology

265 **Azurophilic granules in acute lymphoblastic leukaemia resulting from abundant mitochondria**
D. Hodson, G. Gatward and W. Erber

266 **Epstein–Barr virus-related nasal and cutaneous T-cell lymphoma in an immunosuppressed patient**
N. Sivaji, P. Wardrop, P. Vosylius and R. Jarrett

Reviews

267 **Epstein–Barr virus-associated Hodgkin's lymphoma**
M. K. Gandhi, J. T. Tellam and R. Khanna

282 **Preventing microbial translocation in haematological malignancy**
M. Ellis

Guideline

294 **Guidelines on the diagnosis and management of chronic lymphocytic leukaemia**
D. Oscier, C. Fegan, P. Hillmen, T. Illidge, S. Johnson, P. Maguire, E. Matutes and D. Milligan

Haematological Malignancy

318 **t(11;18)(q21;q21) of mucosa-associated lymphoid tissue lymphoma results from illegitimate non-homologous end joining following double strand breaks**
H. Liu, R. A. Hamoudi, H. Ye, A. Ruskone-Fourmestraux, A. Dogan, P. G. Isaacson and M.-Q. Du

330 **B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia**
R. Ruchlemer, N. Parry-Jones, V. Brito-Babapulle, I. Attolico, A. C. Wotherspoon, E. Matutes and D. Catovsky

337 **Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q−)**
T. Li, Y. Xue, Y. Wu and J. Pan

343 **Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma**
N. Raje, T. Hideshima, F. E. Davies, D. Chauhan, S. P. Treon, G. Young, Y.-T. Tai, D. Avigan, J. Gong, R. L. Schlossman, P. Richardson, D. W. Kufe and K. C. Anderson

Short report 353 **Establishment of a pluripotent preleukaemic stem cell line by expression of the AML1-ETO fusion protein in Notch1-immortalized HSCN1cl10 cells**
C. Delaney and I. D. Bernstein

Transplantation

358 **The London Cord Blood Bank: analysis of banking and transplantation outcome**
S. Davey, S. Armitage, V. Rocha, F. Garnier, J. Brown, C. J. Brown, R. Warwick, D. Fehily, S. Watt, E. Gluckman, A. Vora, M. Contreras and C. V. Navarrete

Platelets, Haemostasis and Thrombosis

Short reports

366 **Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia**
M. Mathias, K. Khair, I. Hann and Ri Liesner

369 **Moderate hypoxia suppresses exercise-induced procoagulant changes**
T. G. DeLoughery, D. G. Robertson, C. A. Smith and D. Sauer

Haemopoiesis and Leucocytes

373 **The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells**
K. Tarte, M. Jourdan, J. L. Veyrune, I. Berberich, G. Fiol, N. Redal, J. Shaughnessy Jr and B. Klein

383 **Frequent *HPRT* mutations in paroxysmal nocturnal haemoglobinuria reflect T cell clonal expansion, not genomic instability**
G. Chen, W. Zeng, S. Green and N. S. Young

392 ***Aspergillus fumigatus* antigens activate innate immune cells via toll-like receptors 2 and 4**
S. Braedel, M. Radsak, H. Einsele, J.-P. Latgé, A. Michan, J. Loeffler, Z. Haddad, U. Grigoleit, H. Schild and H. Hebart

Short report

400 **α-Galactosylceramide-driven expansion of human natural killer T cells is inhibited by prednisolone treatment**
U. Johansson, M. G. Macey, D. Kenny, D. Provan and A. C. Newland

Correspondence

405 **Pulmonary hypertension in two severe combined immunodeficiency disease patients posthaematopoietic stem cell transplantation**
R. G. M. Bredius, M. Ouachee, R. van Brempt, R. Bökenkamp, A. C. Lankester, K. M. Dolman, R. Maarten Egeler and A. Fischer

406 **Non-myeloablative stem cell transplantation for severe combined immunodeficiency – Omenn syndrome**
G. Rossi, M. Zecca, G. Giorgiani, F. Bonetti, P. De Stefano and F. Locatelli

408 **High-dose cyclophosphamide in severe aplastic anaemia**
R. J. Jones and R. A. Brodsky

409 **Response to Drs Jones and Brodsky**
J. C. W. Marsh, S. E. Ball, P. Darbyshire, E. C. Gordon-Smith, A. J. Keidan, A. Martin, S. R. McCann, J. Mercieca, D. Oscier, A. W. W. Roques and J. A. L. Yin on behalf of the British Committee for Standards in Haematology (BCSH) General Haematology Task Force

410 **Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukaemia**
B. Piel, S. Vaidya, D. Lancaster, M. Taj and K. Pritchard-Jones

412 **Response to Piel *et al***
S. Stoneham, L. Lennard, P. Coen, J. Lilleyman and V. Saha

412 **Rh_{null} red blood cells with reduced CD47 do not show increased interactions with peripheral blood monocytes**
P. A. Arndt and G. Garratty

414 **Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma**
M. J. de Vries, A. J. P. Veerman and C. M. Zwaan

415 **Endothelial cell activation and apoptosis in the thrombotic microangiopathies**
J. Laurence

416 **Response to Laurence**
J. J. Jimenez, W. Jy, L. M. Mauro, L. L. Horstman, C. Soderland and Y. S. Ahn

Issue 4, May-II 2004

Images in Haematology

419 **Spontaneous intramural intestinal haemorrhage in a haemophiliac patient**
R. Santoro and P. Iannaccaro

420 **Interstitial pneumonitis during imatinib therapy**
I. Isshiki, K. Yamaguchi and S. Okamoto

Reviews

421 **Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia**
R. Aplenc and B. Lange

435 **Chronic graft *versus* host disease**
M. A. Higman and G. B. Vogelsang

Haematological Malignancy

455 **Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease**
C. Hoffmann, K. U. Chow, E. Wolf, G. Faetkenheuer, H.-J. Stellbrink, J. van Lunzen, H. Jaeger, A. Stoehr, A. Plettenberg, J.-C. Wasmuth, J. Rockstroh, F. Mosthaf, H.-A. Horst and H.-R. Brodt

463 ***FLT-3* aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact**
W. Y. Au, A. Fung, C. S. Chim, A. K. Lie, R. Liang, E. S. K. Ma, C. H. Chan, K. F. Wong and Y. L. Kwong

470 **Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma**
M. A. Hussein, M. Saleh, F. Ravandi, J. Mason, R. M. Rifkin and R. Ellison

Short report 477 **A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis**
M. Schaich, R. Koch, S. Soucek, R. Repp, G. Ehninger and T. Illmer

Transplantation

480 **Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation *versus* peripheral blood stem cell transplantation from a related donor in Japanese patients**
T. E. Tanimoto, T. Yamaguchi, Y. Tanaka, A. Saito, K. Tajima, T. Karasuno, M. Kasai, K. Kishi, T. Mori, N. Maseki, S. Morishima, S. Miyakoshi, M. Kasai, Y. Ohno, S.-W. Kim, A. Numata, M. Kami, Y. Takaue, S. Mori and M. Harada

Platelets, Haemostasis and Thrombosis

494 **Prophylactic effect of recombinant factor VIIa in factor VII deficient patients**
N. C. J. Mathijssen, R. Masereeuw, K. Verbeek, J. M. Lavergne, J.-M. Costa, W. L. van Heerde and I. R. O. Nováková

Haemopoiesis and Leucocytes

500 **Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells**
S. B. Marley, J. L. Lewis, H. Schneider, C. E. Rudd and M. Y. Gordon

512 **Hydrogen peroxide in the Burkitt's lymphoma cell line Raji provides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway**
D. Lu, X.-C. Bai, L. Gui, Y.-C. Su, F. Deng, B. Liu, X.-M. Li, W.-S. Zeng, B.-L. Cheng and S.-Q. Luo

Red Cells and Iron

521 **Four pedigrees of the cation-leaky hereditary stomatocytosis class presenting with pseudohyperkalaemia. Novel profile of temperature dependence of Na^+–K^+ leak in a xerocytic form**
D. M. Gore, M. Layton, A. K. Sinha, P. J. Williamson, B. Vaidya, V. Connolly, P. Mannix, M. C. Chetty, A. Nicolaou and G. W. Stewart

Transfusion

528 **Genetic heterogeneity at the glycosyltransferase loci underlying the GLOB blood group system and collection**
Å. Hellberg, A. Ringressi, V. Yahalom, J. Säfwenberg, M. E. Reid and M. L. Olsson

Correspondence

537 **Erythropoietin receptor defect: a cause of primary polycythaemia**
K. B. Petersen, P. Hokland, G. B. Petersen and C. G. Nyvold

538 **Bone marrow examination in obese patients**
V. Devaliaf and G. Tudor

Book Review

540 **Immune haemolytic anaemias**
M. M. Reid

Announcement

541 **UK NEQAS for Blood Coagulation Annual Meeting**

Issue 5, June-I 2004

Images in Haematology

543 **Schizophrenia and refractory anaemia with ring sideroblasts**
A. Domingo-Claros, E. Alonso and E. de la Banda

544 **Multiple lymphomatous polyposis**
C. Christopoulos, S. Stathakis, I. Theodoropoulos, E. Papavassiliou and S. Savva

Review

545 **Purging iron from the heart**
C. Hershko, M. D. Cappellini, R. Galanello, A. Piga, G. Tognoni and G. Masera

Haematological Malignancy

552 **Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia**
C. J. Harrison, A. V. Moorman, Z. J. Broadfield, K. L. Cheung, R. L. Harris, G. R. Jalali, H. M. Robinson, K. E. Barber, S. M. Richards, C. D. Mitchell, T. O. B. Eden, I. M. Hann, F. G. H. Hill, S. E. Kinsey, B. E. S. Gibson, J. Lilleyman, A. Vora, A. H. Goldstone, I. M. Franklin, J. Durrant and M. Martineau on behalf of the Childhood and Adult Leukaemia Working Parties

560 **E4BP4 expression is regulated by the t(17;19)-associated oncoprotein E2A-HLF in pro-B cells**
J. Yeung, E. O'Sullivan, M. Hubank and H. J. M. Brady

568 **Depletion and impaired interferon-α-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals**
M. Hishizawa, K. Imada, T. Kitawaki, M. Ueda, N. Kadowaki and T. Uchiyama

576 **Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology**
A. Pellagatti, N. Esoof, F. Watkins, C. F. Langford, D. Vetrie, L. J. Campbell, C. Fidler, J. D. Cavenagh, H. Eagleton, P. Gordon, B. Woodcock, B. Pushkaran, M. Kwan, J. S. Wainscoat and J. Boultwood

584 **ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis**
G. Martinelli, E. Cocorocchio, F. Peccatori, E. Zucca, P. C. Saletti, L. Calabrese, R. Pastano, G. Pruneri, C. Mazzetta, M. Ghielmini and F. Cavalli

590 ***WT1* gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single-centre study**
M. Østergaard, L. H. Olesen, H. Hasle, E. Kjeldsen and P. Hokland

Short report 601 **Variant *MYST4-CBP* gene fusion in a t(10;16) acute myeloid leukaemia**
A. Murati, J. Adélade, M.-J. Mozziconacci, C. Popovici, N. Carbuccia, A. Letessier, F. Birg, D. Birnbaum and M. Chaffanet

Transplantation

605 **Infused CD34$^+$ cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy**
A. K. Blystad, J. Delabie, S. Kvaløy, H. Holte, H. Vlerhaugen, I. Ikonomou and G. Kvalheim

613 **Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants**
J. R. Passweg, I. Walker, K. A. Sobocinski, J. P. Klein, M. M. Horowitz and S. A. Giralt on behalf of the Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry

Platelets, Haemostasis and Thrombosis

621 **Genetic variants of the extra-large stimulatory Gs protein alpha-subunit and risk of thrombotic and haemorrhagic disorders**
R. González-Conejero, J. Corral, J. A. Guerrero, J. A. Iniesta, J. Rivera, F. de Arriba and V. Vicente

629 **Mutation of the surface-exposed amino acid Trp^{2313} to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional protein**
S. M. Schatz, K. Zimmermann, M. Hasslacher, R. Kerschbaumer, M. Dockal, H. Gritsch, P. L. Turecek, H. P. Schwarz, F. Dorner and F. Scheiflinger

638 **Secretion of functional plasma haemostasis proteins in long-term primary cultures of human hepatocytes**
C. Biron-Andréani, C. Bezat-Bouchahda, E. Raulet, L. Pichard-Garcia, J.-M. Fabre, J. Saric, J. Baulieux, J.-F. Schved and P. Maurel

647 **The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population**
N. J. Beauchamp, A. C. Dykes, N. Parikh, R. C. Tait and M. E. Daly

Haemopoieses and Leucocytes

655 **Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells**
J. G. Clohessy, J. Zhuang and H. J. M. Brady

666 **Subcellular localization and mobilization of carcinoembryonic antigen-related cell adhesion molecule 8 in human neutrophils**
L. Zhao, M. Furebring, S. Xu and P. Venge

Red Cells and Iron

674 **Early onset hereditary hemochromatosis resulting from a novel *TFR2* gene nonsense mutation (R105X) in two siblings of north French descent**
G. Le Gac, F. Mons, S. Jacolot, V. Scotet, C. Férec and T. Frébourg

Issue 6, June-II 2004

Images in Haematology

679 **Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip**
R. Zeiser, K. Mikesch, P. Fisch, H.-E. Schaefer and J. A. Burger

680 **Aortic thrombus with *Aspergillus* in a patient with refractory acute myelomonocytic leukaemia**
H. Yamamoto, H. Komiya and T. Shirota

Guideline

681 **Guidelines on the diagnosis and management of AL amyloidosis**
J. Bird, J. Cavenagh, P. Hawkins, H. Lachmann, A. Mehta and D. Samson. Compiled by a subgroup of the Guidelines Working Group of the UK Myeloma Forum on behalf of the British Committee for Standards in Haematology: a Subcommittee for the British Society for Haematology

Haematological Malignancy

701 **Adverse prognostic significance of CD20 positive Reed–Sternberg cells in classical Hodgkin's disease**
C. S. Portlock, G. B. Donnelly, J. Qin, D. Straus, J. Yahalom, A. Zelenetz, A. Noy, O. O'Connor, S. Horwitz, C. Moskowitz and D. A. Filippa

709 **Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome**
M. Nakao, S. Horiike, Y. Fukushima-Nakase, M. Nishimura, Y. Fujita, M. Taniwaki and T. Okuda

720 **Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19$^+$ cells *in vivo* and *in vitro***
E. Orsini, A. Pasquale, R. Maggio, E. Calabrese, F. R. Mauro, E. Giammartini, A. Guarini and R. Foa

729 **Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing *PRAME* as a specific discriminating marker**
S. McElwaine, C. Mulligan, J. Groet, M. Spinelli, A. Rinaldi, G. Denyer, A. Mensah, S. Cavani, C. Baldo, F. Dagna-Bricarelli, I. Hann, G. Basso, F. E. Cotter and D. Nizetic

743 **Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β_1 in patients with myeloma**
R. Brown, A. Murray, B. Pope, D. M. Sze, J. Gibson, P. J. Ho, D. Hart and D. Joshua

Transplantation

749 **Haematopoietic stem cell transplantation for refractory autoimmune cytopenia**
J. R. Passweg, M. Rabusin, M. Musso, Y. Beguin, S. Cesaro, G. Ehninger, I. Espigado, A. Iriondo, L. Jost, V. Koza, S. Lenhoff, I. Lisukov, F. Locatelli, A. Marmont, P. Philippe, C. Pilatrino, P. Quartier, J. Stary, P. Veys, J. Vormoor, A. Wahlin, F. Zintl, C. Bocelli-Tyndall, A. Tyndall and A. Gratwohl for the Autoimmune Disease Working Party of the EBMT

756 **Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects**
S. D'Sa, K. Yong, C. Kyriakou, S. Bhattacharya, K. S. Peggs, B. Foulkes, M. J. Watts, S. J. Ings, K. M. Ardeshna, A. H. Goldstone and C. D. Williams

Short report 766 **Treatment of isolated central nervous system relapse in high-risk lymphoid malignancy with allogeneic bone marrow transplantation and extended intrathecal therapy**
Y. Nagatoshi, Y. Kawano, J. Nagayama and J. Okamura

Platelets, Haemostasis and Thrombosis

769 **Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus**
N. Stieltjes, N. Ounnoughene, E. Sava, P. Paugy, V. Roussel-Robert, A. R. Rosenberg, B. Terris, D. Salmon-Cĕron and P. Sogni

777 **Platelet degranulation and monocyte–platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack**
D. J. H. McCabe, P. Harrison, I. J. Mackie, P. S. Sidhu, G. Purdy, A. S. Lawrie, H. Watt, M. M. Brown and S. J. Machin

Red Cells and Iron

788 **Anti-sickling effect of MX-1520, a prodrug of vanillin: an *in vivo* study using rodents**
C. Zhang, X. Li, L. Lian, Q. Chen, O. Abdulmalik, V. Vassilev, C.-S. Lai and T. Asakura

796 **Four new cases of stomatin-deficient hereditary stomatocytosis syndrome: association of the stomatin-deficient cryohydrocytosis variant with neurological dysfunction**
B. Fricke, H. G. Jarvis, C. D. L. Reid, P. Aguilar-Martinez, A. Robert, P. Quittet, M. Chetty, A. Pizzey, T. Cynober, W. F. Lande, W. C. Mentzer, M. von Düring, S. Winter, J. Delaunay and G. W. Stewart

804 **Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria**
J. Simak, K. Holada, A. M. Risitano, J. H. Zivny, N. S. Young and J. G. Vostal

Correspondence

814 **Biological and clinical features of T-biphenotypic acute leukaemia: report from a single centre**
M. Tiribelli, D. Damiani, P. Masolini, A. Candoni, E. Calistri and R. Fanin

815 **Association of the 1513C polymorphism in the P2X7 gene with familial forms of chronic lymphocytic leukaemia**
L.-P. Dao-Ung, S. J. Fuller, R. Sluyter, K. K. SkarRatt, U. Thunberg, G. Tobin, K. Byth, M. Ban, R. Rosenquist, G. J. Stewart and J. S. Wiley

817 **Severe factor XI deficiency caused by compound heterozygosity**
L. Dai, M. Mitchell, P. Carson, D. Creagh, J. Cutler, G. Savidge and A. Alhaq

818 **Long-term improvement of anaemia in a patient with aplastic anaemia by short-term administration of pegylated recombinant human megakaryocyte growth and development factor**
A. Matsuda, M. Misumi, M. Ishikawa, F. Yagasaki, I. Jinnai, M. Bessho and H. Mizoguchi

821 **Erratum**

822 **Author Index**

826 **Keyword Index**